

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

https://marketpublishers.com/r/B4FFD4C9DCEEN.html

Date: April 2013

Pages: 105

Price: US\$ 3,400.00 (Single User License)

ID: B4FFD4C9DCEEN

Abstracts

"BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 154 tables & figures. The Chinese biopharmaceutical market is presented as follows:

By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)

By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

Company financials, sales & revenue figures

China GDP, economic growth, export (bulk drug, formulations) figures



Indian health expenditure as a function of GDP

Growth change figures of emerging and developing countries (India, Russia, China, Brazil)

Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market

Top Five Contract Pharmaceutical Export Markets of China

Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)

Multinational penetration into the Chinese Pharma Market

Comprehensive product portfolios, R&D activity and pipeline therapeutics

M&A activity and future strategies of top Chinese pharmacos

Economic indicators, trade policy, merchandise and commercial trade statistics

Gross Domestic Product of China, historic and projection analysis

Chinese economic outlook in comparison to advanced economies


Three Tier 'Pharmerging' Markets with Potential for Significant Growth

Prescription drug sales distribution channels in China

Major biogeneric products in China



This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.



Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends



that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

An in-depth understanding of the Chinese biopharmaceutical market and it's environment

Current market facts, figures and product lines of key players in the industry

An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market

Knowledge of how the Chinese biopharma market will integrate into the global healthcare market

Information on key regulatory and government policies

Data on levels of private and publically funded biopharma studies in China

Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

Lack of regulatory policy and legislation

Reimbursement schemes and payers concerns

Funding and government sponsorship issues

International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

Strong, competitive players



Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity



Contents

1 SUMMARY

- 1.1 Objectives of Report
- 1.2 Scope of Study
- 1.3 Data Sources and Methodology
- 1.4 Key Findings and Observations
- 1.5 Executive Summary

2 CHRONIC DISEASE PREVALENCE STATISTICS

3 BUSINESS ENVIRONMENT

- 3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
- 3.2 Gross Domestic Product of China, Historic and Projection Analysis
- 3.3 Annual Health Expenditure in China, Historic and Projected Analysis
- 3.4 Global and Chinese Economic Outlook 2010-2013
- 3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries
- 3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe)

4 CHINESE PHARMACEUTICAL MARKET

- 4.1 Market Overview
- 4.2 Main Players in China's Pharmaceutical Industry
- 4.3 Anti-Allergic Drug Market
- 4.4 Asthma Drug Market
- 4.5 Benign Prostate Hyperplasia Drug Market
- 4.6 Anti-depressant Drug market
- 4.7 Dermatitis Drug Market
- 4.8 Diabetic Drug Market
- 4.9 Hypertension Drug Market
- 4.10 Dyslipidaemia Drug Market
- 4.11 Senile Dementia Drug Market
- 4.12 Cancer Drug Market
- 4.13 Rheumatoid Arthritis Drug Market
- 4.14 Ophthalmological Drug Market



- 4.15 Liver Disease Drug Market
- 4.16 Antibiotic Drug Market

5 GOVERNMENT AND REGULATION ENVIRONMENT

- 5.1 12th Five Year Plan
- 5.2 Intellectual Property for Pharmaceuticals in China
- 5.3 State Food and Drug Administration (SFDA)
- 5.4 Pharmaceutical Distribution Process in China

6 CHINA - THIRD LARGEST PHARMA MARKET 2012

- 6.1 China At the Forefront of Emerging Markets
- 6.2 Generic Medication Market and China
- 6.3 Novel Product Drug development
- 6.4 Drug Development Cost (Change heading)
- 6.5 Drug Development Case Study Beijing Continent Pharmaceuticals
- 6.6 China's Pharmaceutical Export Market
- 6.7 Spot Light China Medical City Taizhou

7 GLOBAL PHARMACEUTICAL COMPANIES INTEREST IN CHINA

- 7.1 Abbott China
- 7.2 AstraZeneca China
- 7.3 AstraZeneca Products in China
- 7.4 Boehringer Ingelheim China
- 7.5 Eli Lilly China
- 7.6 GlaxoSmithKline China
- 7.7 Johnson & Johnson Medical China
- 7.8 Merck China
- 7.9 Novartis China
- 7.10 Pfizer China
 - 7.10.1 Pfizer China R&D Centre
 - 7.10.2 Pfizer China Products
- 7.11 Roche China

8 CHINESE PHARMACEUTICAL COMPANIES

8.1 Amoytop Biotech



- 8.2 Active Pharmaceutical Products
 - 8.2.1 Research and Development
 - 8.2.2 Financial Information
- 8.3 Beijing Continent Pharmaceuticals
- 8.4 FusoGen Pharmaceuticals
 - 8.4.1 Financial Information
- 8.5 Shanghai Huaguan Biochip
 - 8.5.1 Financial Information
- 8.6 SiBiono GeneTech
 - 8.6.1 Financial Information
- 8.7 Sinovac Biotech
 - 8.7.1 Financial Information
 - 8.7.2 New Products
 - 8.7.3 Split viron pandemic influenza vaccine
 - 8.7.4 RabEnd
 - 8.7.5 Pipeline Portfolio
 - 8.7.6 EV71 virus Vaccine
 - 8.7.7 Pneumococcal Conjugate Vaccine
 - 8.7.8 Pneumococcal Polysaccharide Vaccine
 - 8.7.9 Varicella Vaccine
 - 8.7.10 Measles, Mumps and Rubella Vaccines
 - 8.7.11 Rotavirus Vaccine

9 DRIVERS, RESTRAINTS, CHALLENGES AND OPPORTUNITY ANALYSIS

- 9.1 Key Drivers of the Biopharmaceutical Market in China
- 9.2 Key Restraints of the Biopharmaceutical Market in China
- 9.3 Challenges of the Pharmaceutical Industry in China
- 9.4 Opportunities Within BioPharma China



List Of Tables

LIST OF TABLES

Table 2 1:	Most	Prominent	Cancer	Manifestations	in	China
I abic Z. I.	IVIOSI		Caricor	IVIAI III CSIAIIOI IS		OHIIIIA

- Table 2.2: Top Fifty Diseases in China Today (non-cancer)
- Table 2.3: Top Infectious Disease States in China Today
- Table 3.1: World Trade Organisation Basic Indicators on China
- Table 3.2: World Trade Organisation Trade Policy of China
- Table 3.3: World Trade Organisation Merchandise Trade Statistics: China
- Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China
- Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve
- Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected
- Payments Due and Monthly Historical Transactions of China
- Table 3.6: China Statistics
- Table 4.1: Top Global Pharma Markets 2003-2013
- Table 4.2: Major Players in China's Anti-Allergy Drug Market
- Table 4.3: Major Players in China's Asthma Drug Market
- Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market
- Table 4.5: Major Players in China's Anti-Depressant Drug Market
- Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated

Therapeutics

- Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market
- Table 4.8: Major Players in China's Dermatitis Drug Market
- Table 4.9: Major Players in China's Diabetic Drug Market
- Table 4.10: Major Players in China's Hypertension Drug Market
- Table 4.11: Major Players in China's Dyslipidaemia Drug Market
- Table 4.12: Major Players in China's Senile Dementia Drug Market
- Table 4.13: Major Players in China's Cancer Drug Market
- Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market
- Table 4.15: Major Players in China's Ophthalmological Drug Market
- Table 4.16: Major Players in China's Liver Disease Drug Market
- Table 4.17: Major Players in China's Antibiotic Drug Market
- Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015
- Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012
- Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China
- Table 5.4: Prescription Drug Sales Distribution Channels in China



- Table 6.1: Major Biogeneric Products in China
- Table 6.2: Imported Therapeutics with Administrative Protection in China
- Table 6.3: Expired Proprietary Biopharmaceuticals in China
- Table 6.4: Reasons Why Multinational Companies Seek CMO's in China
- Table 6.5: Comparison of Clinical Trial Cost between China and the USA
- Table 6.6: Five Functional Districts of China Medical City
- Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City
- Table 7.1: Top Multinational Company Performance, China 2011 Q1
- Table 7.2: Abbott Areas of Expertise
- Table 7.3: Abbott Key Global Products
- Table 7.4: Abbott China Anaesthesia Product Profile
- Table 7.5: Abbott China Cardiovascular Product Profile
- Table 7.6: Abbott China Vaccine Product Profile
- Table 7.7: Abbott China Digestion Product Profile
- Table 7.8: Abbott China HIV Product Profile
- Table 7.9: Abbott Rheumatology HIV Product Profile
- Table 7.10 Abbott China Gynaecological Product Profile
- Table 7.11 Abbott China Urological Product Profile
- Table 7.12 Abbott China Liver Disease Product Profile
- Table 7.13 Abbott China Diagnostic Product Profile
- Table 7.14: Abbott China Molecular Diagnostic Product Profile
- Table 7.15: Abbott Blood Glucose Meter Product Profile
- Table 7.16: Abbott Cardiovascular Product Profile
- Table 7.17: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile
- Table 7.18: Important Milestones in AstraZeneca China's History
- Table 7.19: AstraZeneca China Anaesthetic Range of Products
- Table 7.20: AstraZeneca China Cardiovascular and Metabolism Range of Products
- Table 7.21: AstraZeneca China Gastrointestinal Range of Products
- Table 7.22: AstraZeneca China Infection Range of Products
- Table 7.23: AstraZeneca China Neurology Range of Products
- Table 7.24: AstraZeneca China Oncology Range of Products
- Table 7.25: AstraZeneca China Respiratory Range of Products
- Table 7.26: Bayer China Important Milestones
- Table 7.27: Bayer Leading Therapeutics in China
- Table 7.28: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China
- Table 7.29: Boehringer Ingelheim Major Products in China
- Table 7.30: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
- Table 7.31: Global Therapeutic Pipeline, Boehringer Ingelheim
- Table 7.32: Major Global Boehringer Ingleheim Therapeutic Products



- Table 7.33: GlaxoSmithKline Prescription Portfolio and Indications in China
- Table 7.34: GlaxoSmithKline Vaccine Portfolio and Indications in China
- Table 7.35: GlaxoSmithKline Over the Counter Portfolio and Indications in China
- Table 7.36: Significant Milestones in Johnson and Johnson China History
- Table 7.37: Merck Serono Pharmaceutical Key Therapeutic Areas in China
- Table 7.38: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
- Table 7.39: Merck Serono Therapeutic Portfolio in China
- Table 7.40: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
- Table 7.41: Range of Diabetic Products from Novo Nordisk China
- Table 7.42: QUICKFACTs Pfizer China
- Table 7.43: Important Milestones Pfizer China
- Table 7.44: Pfizer China Range of Infectious Disease Therapeutics for Chinese Health Care Market
- Table 7.45: Pfizer China Range of Mental Health Products for Chinese Health Care Market
- Table 7.46: Pfizer China Range of Genitourinary Products for Chinese Health Care Market
- Table 7.47: Pfizer China Range of Endocrine Products for Chinese Health Care Market
- Table 7.48: Pfizer China Range of Women's Health Products for Chinese Health Care Market
- Table 7.49: Pfizer China Range of Cardiovascular Disease Products for Chinese Health Care Market
- Table 7.50: Pfizer China Range of Oncology Products for Chinese Health Care Market
- Table 7.51: Pfizer Key Consumer Healthcare Global Products
- Table 7.52: Pfizer Key Speciality Care Global Products
- Table 7.53: Pfizer Key Oncology Global Products
- Table 7.54: Pfizer Key Global Established Products
- Table 7.55: Pfizer Key Innovative Products in Emerging Markets
- Table 7.56: Pfizer Key Animal Health Global Products
- Table 7.57: Roche Pharmaceuticals Product List in China
- Table 7.58: Seven Growth Platforms of Sanofi China
- Table 7.59: Key Therapeutic Areas of Sanofi China
- Table 8.1: Important Milestones in Amoytop Biotech's Development
- Table 8.2: Current Recombinant protein therapeutics by Amoytop Biotech
- Table 8.3: Active Pharmaceutical Product Portfolio of Amoytop Biotech
- Table 8.4: Milestones Achieved by FusoGen Pharmaceuticals
- Table 8.5: Research and Development Sub-groups of FusoGen Pharmaceuticals
- Table 8.6: Shanghai Huaguan Biochip Rapid Test Portfolio



Table 8.7: Shanghai Huaguan Biochip Laboratory Service Portfolio

Table 8.8: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBono GeneTech

Table 8.9: Gendicine - Potential Oncology Indications for Future Approval

Table 8.10: Current Human Vaccine Portfolio of Sinovac Biotech

Table 8.11: Important Milestones in the History of Sinovac Biotech

Table 8.12: Pipeline Portfolio of Sinovac Biotech

Table 8.13: Total Sales Figures Sinovac Biotech 2007-2011

Table 9.1: Key Drivers of the Biopharmaceutical Market in China

Table 9.2: Key Restraints of the Biopharmaceutical Market in China

Table 9.3: Key Challenges of the Pharmaceutical Market in China

Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020

Table 9.5: Leading Biopharmaceutical Areas with Significant Opportunities in China



List Of Figures

LIST OF FIGURES

- Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages
- Figure 3.1: China GDP Figures 2006-2015
- Figure 3.2: Annual Health Expenditure in China 2006-2015
- Figure 3.3: Global and Emerging Market and Developing Countries Economic Growth Change 2010-2013
- Figure 3.4: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013
- Figure 3.5: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013
- Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
- Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
- Figure 3.8: Global, US and Germany Economic Growth 2010-2013
- Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017
- Figure 3.10: Global, France and Italy Economic Growth 2010-2013
- Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
- Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013
- Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017
- Figure 4.1: The Chinese Healthcare Industry by Sector, 2011
- Figure 4.2: Anti-Depressant Market Share, China 2009 Figures (Percentage)
- Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020
- Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs
- Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials
- Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market
- Figure 5.5: Revenue Share (Billion \$) of Major Players in Chinese Pharmaceutical Distribution Market
- Figure 6.1: Three Tier 'Pharmerging' Markets with Potential for Significant Growth
- Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010



Figure 6.3: Number of New Drug Applications in China 2003-2010

Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China

Figure 6.5: Percentage of Clinical Trial Drug by Disease State

Figure 6.6: China's Regional Pharmaceutical Processing Trade Export Market Share Percentage 2010

Figure 6.7: Contract Amount of China's Regional Pharmaceutical Processing Trade Export, 2010

Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China, 2010

Figure 7.1: Abbottt – Business Specialization Strategy 2012: Diversified Medical

Products and Research-Based Pharmaceuticals

Figure 7.2: Abbott Diversified Medical Product Portfolio

Figure 7.3 Business Sectors – Pfizer China

Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression

Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service

Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2011

Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2011

Figure 8.5: Reported Sales of Healive Vaccine, 2009-2011

Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2011

Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2011

Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011



I would like to order

Product name: BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese

Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers,

Restraints, Opportunities & Challenges

Product link: https://marketpublishers.com/r/B4FFD4C9DCEEN.html

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B4FFD4C9DCEEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970